Beyond 2017 ─ Leveraging global traceability for sustainable business and growth
Serialisation, combined with track and trace mechanisms, are being seen as an important solution to ensure that substandard or counterfeit medicines are discovered and recalled from global markets.
In order to secure the health of their citizens from counterfeit medicines, more than 40 countries across the globe are already implementing or set to enforce track & trace and serialization mandates by 2018.
Pharmaceutical companies across the world are in various phases of implementing and executing serialization strategies. As companies in India continue along the learning curve, they are realizing the drawbacks of piecemeal solutions. Thus, it is strategic business sense to make traceability the cornerstone of sustainable future growth.
Express Pharma and OPTEL Group, present Pharma CXO Summit: Beyond 2017 ─ Leveraging global traceability for sustainable business and growth
It will present insights from regulators and policy makers, as well as case studies from the early adopters of traceability technologies. The case studies will be from both global as well as Indian experts who have headed serialization strategies in their companies.
Attendees at Pharma CXO Summit will have the opportunity to share their experiences, pain points and gain practical solutions to future proof their strategies while extracting maximum ROI.
Topics to be covered
- Leveraging global traceability for sustainable business & growth
- Learning from serialization stalwarts: Global case studies
- Serialization strategies for biologics
- Serialization strategies for pharmaceutical companies
- Serialization strategies for CMOs
- Opportunities and challenges in India’s serialization journey
The Indian pharma industry has come a long way in 70 years of independence. Initially spurred by a nationalistic mission to make our country self sufficient in medicines, the sector today provides ‘Made in India’ medicines to patients across the world, earning India the title, ‘Pharmacy of the World’. According to IBEF, India is the largest supplier of generic medicines globally (20 per cent of global export volume).
Pharma exports from India stood at $16.4 billion in 2016-17, and is expected to reach $20 billion by 2020. What’s more, US Food and Drug Administration (US FDA) approvals to Indian companies have almost doubled to 201 in FY2015-16, up from 109 approvals received in FY2014-15.
India’s advantage as an export destination lies in the economics. Manufacturing costs in our country are among the lowest in the world, approximately 35–40 per cent of that in the US. Added to that, our talent pool is deep. However, with other countries eating into the global pharma exports pie, Indian pharma companies need to evolve their export strategies. In recognition of the untiring efforts of pharma exporters, Express Pharma is launching the Express Pharma Export Excellence Awards.
It is an endeavour to acknowledge and celebrate the resounding successes of Indian pharma companies, and the vital roles they have played in establishing India as a leading export destination.
The Express Pharma Export Excellence Awards 2017 will be selected by a Jury and based on revenue from exports in two categories:
Click Below for the Nomination Forms
Last date for receiving nominations: October 27, 2017
For more information, write to us at email@example.com
Pharma Export Excellence Handbook 2017 will feature strategies that leading Indian pharma exporters have adopted to create an unassailable edge and leading positions. While some have chosen to excel in a particular category, others have crafted their geographical footprint with great care.
In order to share their learnings with the larger pharma fraternity, the Pharma Export Excellence Handbook 2017 will feature company profiles and insights from pharma professionals in key roles, who have steered companies to global leadership positions.
Click here to get featured in the Pharma Export Excellence Handbook 2017